Glycocalyx damage biomarkers in healthy controls, abdominal surgery, and sepsis: a scoping review.


Journal

Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
ISSN: 1366-5804
Titre abrégé: Biomarkers
Pays: England
ID NLM: 9606000

Informations de publication

Date de publication:
Sep 2020
Historique:
pubmed: 1 7 2020
medline: 2 6 2021
entrez: 30 6 2020
Statut: ppublish

Résumé

Despite wide interest in glycocalyx biomarkers, their values in healthy individuals, patients after abdominal surgery, and septic patients have been poorly understood. We searched MEDLINE, CENTRAL and EMBASE for papers measured glycocalyx biomarkers in healthy individuals, patients after abdominal surgery and septic patients. We extracted 3948 titles and identified 58 eligible papers. Syndecan 1 was the most frequently measured biomarker (48 studies). Its mean or median value in healthy individuals varied to a biologically implausible degree, from 0.3 to 58.5 ng/ml, according to assay manufacturer. In post-operative patients, syndecan 1 levels increased after pancreatic surgery or liver surgery, however, they showed minor changes after hysterectomy or laparoscopic surgery. In septic patients, biomarker levels were higher than in healthy volunteers when using the same assay. However, six healthy volunteer studies reported higher syndecan 1 values than after pancreatic surgery and 24 healthy volunteer studies reported higher syndecan 1 values than the lowest syndecan 1 value in sepsis. Similar findings applied to other glycocalyx biomarkers. Glycocalyx damage biomarkers values are essentially defined by syndecan 1. Syndecan 1 levels, however, are markedly affected by assay type and show biologically implausible values in normal, post-operative, or septic subjects.

Identifiants

pubmed: 32597227
doi: 10.1080/1354750X.2020.1787518
doi:

Substances chimiques

Biomarkers 0
SDC1 protein, human 0
Syndecan-1 0

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

425-435

Auteurs

Fumitaka Yanase (F)

Department of Intensive Care, Austin Hospital, Melbourne, Australia.
Australian and New Zealand Intensive Care Research Centre, Monash University School of Public Health and Preventive Medicine, Melbourne, Australia.

Thummaporn Naorungroj (T)

Department of Intensive Care, Austin Hospital, Melbourne, Australia.
Department of Intensive Care, Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Rinaldo Bellomo (R)

Department of Intensive Care, Austin Hospital, Melbourne, Australia.
Australian and New Zealand Intensive Care Research Centre, Monash University School of Public Health and Preventive Medicine, Melbourne, Australia.
Centre for Integrated Critical Care, Department of Medicine and Radiology, University of Melbourne, Melbourne, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH